<div id="readability-page-1"><p>Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 4,540,000 shares,  a decline of 57.3% from the September 15th total of 10,630,000 shares. Based on an average daily trading volume, of 4,200,000 shares, the days-to-cover ratio is presently 1.1 days. Based on an average daily trading volume, of 4,200,000 shares, the days-to-cover ratio is presently 1.1 days.</p><div><p><span></span><span>Get <strong>Microbot Medical</strong> alerts:</span></p></div><h2>Hedge Funds Weigh In On Microbot Medical</h2><ul><li>Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs</li></ul><p>Large investors have recently bought and sold shares of the company. U.S. Capital Wealth Advisors LLC purchased a new position in  Microbot Medical during the 2nd quarter worth $25,000.  American Century Companies Inc. purchased a new position in  Microbot Medical during the 2nd quarter worth $32,000.  Beacon Capital Management LLC raised its position in  Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock worth $40,000 after buying an additional 10,000 shares during the last quarter.  Virtu Financial LLC purchased a new position in  Microbot Medical during the 1st quarter worth $42,000.  Finally, XTX Topco Ltd purchased a new position in  Microbot Medical during the 2nd quarter worth $43,000. Hedge funds and other institutional investors own  16.30% of the company's stock. </p><h2>Microbot Medical Price Performance</h2><p>MBOT stock opened at $2.76 on Friday. The company has a fifty day moving average price of $3.38 and a 200 day moving average price of $2.79. Microbot Medical has a 12 month low of $0.89 and a 12 month high of $4.67. The company has a market cap of $185.36 million, a price-to-earnings ratio of -4.76 and a beta of 1.25. </p><ul><li>Microbot Medical spikes 150% on its Endovascular Surgical Robot</li></ul><p>Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.02).  As a group, analysts anticipate that  Microbot Medical will post -0.71 earnings per share for the current year. </p><h2>Analyst Ratings Changes</h2><p>Several brokerages have recently weighed in on MBOT. HC Wainwright  restated a &#34;buy&#34; rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Wednesday. Wall Street Zen upgraded shares of Microbot Medical from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Friday, October 3rd. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Microbot Medical in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Microbot Medical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, August 21st. One research analyst  has rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $12.00.</p><p><b>Read Our Latest Report on Microbot Medical</b></p><h2>About Microbot Medical</h2> (Get Free Report)<p>Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.</p><h2>See Also</h2><ul><li>Five stocks we like better than Microbot Medical</li><li>5 Top Rated Dividend Stocks to Consider</li><li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li><li>Why Are These Companies Considered Blue Chips?</li><li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li><li>Most Volatile Stocks, What Investors Need to Know</li><li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Microbot Medical Right Now?</h2><p>Before you consider Microbot Medical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.</p><p>While Microbot Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MBOT

<p>Microbot Medical Inc. (NASDAQ:MBOT) experienced a significant decline in short interest, dropping 57.3% from 10,630,000 shares to 4,540,000 shares as of September 30th. The short-interest ratio is currently 1.1 days based on an average daily volume of 4,200,000 shares. The stock opened at $2.76, with a market cap of $185.36 million. Analysts have mixed ratings, with a consensus rating of "Hold" and an average target price of $12.00. The company focuses on developing robotic endoluminal surgery devices for minimally invasive procedures.</p>

Short Interest in Microbot Medical Inc. (NASDAQ:MBOT) Declines By 57.3%